

ZAHRA MADJD, MD PhD

PERSONAL DETAILS

Professor, Dep of Pathology, School of Medicine, Iran University of Medical Sciences (IUMS)
 Head, Dep of Molecular Medicine, Faculty of Advanced Technologies in Medicine, IUMS
 Oncopathology Research Centre, IUMS
 Address: Hemmat Highway, Next to Milad tower, Tehran, Iran, Post code: 14496-14525
 Tel/fax:+982188622608
zahra.madjd@yahoo.com, majdjabari.z@iums.ac.ir



Professor Zahra Madjd, MD, Ph.D., conducted her Ph.D. from the Department of Oncology, University of Nottingham, and is currently a professor of immunopathology at “The Department of Pathology” & “Oncopathology Research Center”, Iran University of Medical Sciences."

Academic Activities

Position	Dates	Place
Professor	Feb 2018 -present	Dep Pathology, Iran University of Medical Sciences (IUMS)
Visiting Professor	March – Sep 2018	Dep Urologic Sciences, Vancouver Prostate Centre, UBC, Canada
Core member of Council, IUMS	2018-2021	Iran University of Medical Sciences
Head, Cancer Stem Cells Committees	2016-2018	National Committee for Stem Cell Sciences and Technologies
Visiting Scientist	2014	Molecular Medicine Lab, Dep Dermatology, UBC, Vancouver, Canada
Member of National Board of Biotechnology and Molecular Medicine	2013-present	Ministry of Health and Medical Education
Head of Research Centres Coordinating Office (RCCO)	2013	Iran University of Medical Sciences
Associate Professor	2012- 2018	Dep of Pathology, IUMS
Head, Dep Molecular Medicine	2009- present	Faculty of Advanced Technologies in Medicine,
Co-founder , Research Director of Oncopathology Research Centre	2007 - present	Iran University of Medical Sciences
Core member of Cancer Research Centre (CRC)	2007 - present	Shahid Beheshti University, Shohada Hospital, Tehran
Member of Research Committee	2007- present	Dep Pathology, IUMS
Assistant Professor	2006-2012	Dep of Pathology, School of Medicine, IUMS

Appointed for Post doctorate Scientist (Prof Shila Bingha)	2006	University of Cambridge, Addenbrock's Hospital, MRC
Post-doctoral Research Fellow (Prof Lindy Durrant)	2005-2006	CRUK Clinical Oncology, University of Nottingham, Nottingham, UK
PhD, Cancer Immunology (Prof Lindy Durrant, Prof Ian. O Ellis)	2001- 2005	CRUK Clinical Oncology, University of Nottingham, City Hospital, Nottingham, UK
MSc (selected courses, Oncology)	2000-2001	University of Nottingham, UK
Medical practice (GP)	1996- 2000	Torab Health Center, Tehran, Iran
Doctorate in Medicine (MD)	1988 -1996	Tehran, Iran

Grants

1. Grant by Stem cell Foundation, **July 2024**
2. Grant by: Iran National Science Foundation: INSE, Nano committee, **March 2024**
3. Grants by Iran University of Medical Sciences (IUMS), as distinguished researcher with H-Index>30 (**May 2023**), Application of Artificial Intelligence (AI) in histopathology scoring.
4. Grants (4 times) by “Natal Institute for Medical Reserch Development, NIMAD”, as distinguished researcher with high H-Index (**2016, 2017, 2018, 2023**)
5. National Major Grant, Research and Technology Office, Ministry of Health and Medical Education, for “Cancer Stem Cells in Gastrointestinal Cancers” equipment setup (**March 2016**)
6. Research Grant, Research and Technology Office, Ministry of Health and Medical Education, to equip a special culture room for Cancer Stem Cell Research (**Dec 2015**)
7. Grant by “Iran National Science Foundation: for project on Renal Cancer Stem Cells (**Oct 2015**)

Honours and Prizes

- 1) EACR-18 (European Association of Cancer Research) award, July 2004, Insbruke, Austria.
- 2) BACR (British Association of Cancer Research) award , ECCO13 meeting, October 2005, Paris
- 3) BACR award at the EACR 20, July 2008, Lyon, France
- 4) Young Researcher award, Iranian Ministry of Health and Education, December 2008
- 5) Distinguished Researcher award , Iran University of Medical Sciences, Dec 2014
- 6) Distinguished Researcher award (high H-Index) , Iran University of Medical Sciences, Dec 2017
- 7) Distinguished Researcher award (high H-Index) , Iran University of Medical Sciences, August 2019

Research Interests:

- 1) Cancer Stem cells (CSCs)
- 2) Therapeutic Antibodies, Antibody-Drug Conjugates
- 3) Cancer Immunotherapy, Cancer Vaccine
- 4) Circulating Tumour Cells (CTCs)
- 5) Translational Cancer Research
- 6) Tumour Biomarkers
- 7) CAR T Cells/ CAR NK cells

Background Education:

1. MD dissertation: “Characteristics of thyroid disorders before and after iodized salt consumption in Tehran during 1993-5”. Supervisor: Professor Freidoon Azizi

2. PhD project: Expression of complement regulatory proteins (CIPs) and MHC class I molecules in breast carcinomas. These antigens (CIPs) are targets for monoclonal antibody therapy (mab), as over-expression of CIPs limits the effectiveness of mab therapy. Prof Lindy Durrant & Prof an Ellis, University of Nottingham, UK

3. Post-doctoral Research Fellow. Study of immune-surveillance pathway in Breast tumours, colorectal cancer, supervisor: Prof Lindy Durrant, University of Nottingham

4. Sabbatical. Visiting Scientist (2014) Molecular Medicine Lab, Dep Dermatology, UBC, Canada, Biomarkers in Melanoma

5. Sabbatical/ Fellowship. Visiting Professor (2018), Dep Urologic Sciences, Vancouver Prostate Centre, UBC, Canada. SEMA3C expression on bladder and renal cell carcinomas for targeted therapy.

PUBLICATIONS:

h- Index (Scopus) =35

h- Index (Google scholar) =41

2023-2024

1. Advanced co-culture 3D breast cancer model to study cell death and nanodrug sensitivity of tumor spheroids. Akram Ahvaraki, Elmira Gheytauchi, Ebrahim Behroodi, Hamid Latifi, Faezeh Vakhshiteh, Zeinab Bagheri, Zahra Madjd, June 2024. *Biochemical Engineering Journal*.
2. Higher expression of SALL4-A isoform is correlated with worse outcomes and progression of the disease in subtype of testicular germ cell tumors. Niknam Lakpour, Roya Ghods, Maryam Abolhasani, Leili Saeednejad Zanjani, Kioomars Saliminejad, Elham Kalantari, Sima Saki, Mohammad Mehdi Ranjbar, Leila Balay-Goli, Mohammad Reza Sadeghi, Zahra Madjd. May 2024. *Biomarkers*. Pages 1-47.
3. Metabolic Fingerprinting of Serum and Seminal Plasma of Testicular Cancer Patients Using Raman Spectroscopy: A Pilot Study. Niknam Lakpour, Mohammad Reza Sadeghi, Naser Jafarzadeh, Ralf Henkel, Azadeh Hajiparvaneh, Zohreh Fathi, Roya Ghods, Kambiz Gilany, Zahra Madjd, March 2024. *Journal of Reproduction & Infertility*.
4. Which approach, biosensors or molecular biology techniques, offers a more effective and reliable method for detecting circular RNAs in cancer? Y Vojgani, Z Madjd, L Yesharim, L Golami, S Saeedi, J Kiani, M Karimi, *Microchemical Journal*, Apr 2024.
5. Clinical significance of CD166 and HER-2 in different types of gastric cancer, L Moradi, F Tajik, L Saeednejad Zanjani, M Panahi, E Gheytauchi, .. Madjd Z, *Clinical and Translational Oncology*. July 2023, 26 (3), 664-681.
6. Novel neutralizing SARS-CoV-2-specific mAbs offer detection of RBD linear epitopes. SMM Zadeh, AA Bayat, H Shahsavarani, F Karimi-Busheri, J Kiani, ..., Z Madjd, *Virology Journal* 21 (1), 37.
7. Clinico-Pathological and Prognostic Significance of a Combination of Tumor Biomarkers in Iranian Patients With Breast Cancer. MH Makoui, M Mobini, S Fekri, L Geranpayeh, HM Tabriz, Z Madjd, *Clinical Breast Cancer* 24 (1), e9-e19.

8. Combination of anti-miR19a-3p polyplex plus doxorubicin for breast cancer in 2D culture and apoptosis assay in 3D spheroids in a microwell device. BKY Azar, M Nourbakhsh, MR Nasirae, K Mousavizadeh, Z Majd,Journal of Micromechanics and Microengineering 34 (1), 015002
9. Nuclear overexpression of DNA damage-inducible transcript 4 (DDIT4) is associated with aggressive tumor behavior in patients with pancreatic tumors. F Tajik, F Fattahi, F Rezagholizadeh, B Bouzari, P Babaheidarian, ...Z Majd. Scientific Reports 13 (1), Nov 2023.
10. Quantitative measurement of CA 15-3 cancer biomarker using an electrochemical aptasensor based on the electrodeposition of Au thin film on cauliflower-like rGO-MoS₂ nanocomposite. Y Vojgani, S Ranjbar, N Naseri, A Dolati, Z Majd, J Kiani, S Saeedi, ..Z Majd, Microchimica Acta 190 (10), 406.
11. COVID-19 pandemic impact on screening and diagnosis of prostate cancer: a systematic review. SMM Zadeh, F Tajik, E Gheytauchi, J Kiani, R Ghods, Z Majd, BMJ Supportive & Palliative Care. 2023
12. Engineering chimeric autoantibody receptor T cells for targeted B cell depletion in multiple sclerosis model: An in-vitro study. M Sahlolbei, M Azangou-Khyavy, J Khanali, B Khorsand, A Shiralipour, ...Z Majd. Heliyon 9 (9). 2023
13. Heterotypic tumor spheroids: a platform for nanomedicine evaluation Faezeh Vakhshiteh , Zeinab Bagheri, Marziye Soleimani , Akram Ahvaraki , Parisa Pournemat, Seyed Ebrahim Alavi and Zahra Madjd,Journal of Nanobiotechnology, August(2023) 21:249
14. Tumor matrix stiffness provides fertile soil for cancer stem cells. Sadegh Safaei, Roya Sajed, Ahmad Sharifabrizi, Shima Dorafshan, Leili Saeednejad Zanjani, Masoumeh Dehghan Manshadi, Zahra Madjd and Roya Ghods, Cancer Cell Int, 23:143,(July 2023).
15. Novel Monoclonal Antibodies Specific for Human Ki67 and P53 Tumor Markers in Breast Cancer Tissue Samples. Hassanzadeh Makoui M, Mobini M, Khoshnoodi J, Bahadori T, Golsaz-Shirazi F, Moradi Tabriz H, **Madjd Z**, Jeddi-Tehrani M, Zarnani AH, Amiri MM, Shokri F. Iran J Immunol. 2023 May 7;20(2). doi: 10.22034/iji.2023.96926.2469
16. High expression of Talin-1 is associated with tumor progression and recurrence in melanoma skin cancer patients. Rezaie Y, Fattahi F, Mashinchi B, Kamyab Hesari K, Montazeri S, Kalantari E, **Madjd Z**, Saeednejad Zanjani L.BMC Cancer. 2023 Apr 3;23(1):302. doi: 10.1186/s12885-023-10771-z.

17. Gheytauchi E, Tajik F, Razmi M, Babashah S, Cho WCS, Tanha K, Sahlolbei M, Ghods R, **Madjd Z.**Cancer Cell Int. 2023 Jan 20;23(1):10. doi: 10.1186/s12935-023-02851-8
18. Efficacy of Whole Cancer Stem Cell-Based Vaccines: A Systematic Review of Preclinical and Clinical Studies. Hashemi F, Razmi M, Tajik F, Zöller M, Dehghan Manshadi M, Mahdavinezhad F, Tiyyuri A, Ghods R, **Madjd Z.** Stem Cells. 2023 Mar 17;41(3):207-232. doi: 10.1093/stmcls/sxac089
19. Combination of androgen receptor inhibitor enzalutamide with the CDK4/6 inhibitor ribociclib in triple negative breast cancer cells. Choupani E, **Madjd Z,** Saraygord-Afshari N, Kiani J, Hosseini A.PLoS One. 2022 Dec 22;17(12):e0279522. doi: 10.1371/journal.
20. Prognostic value of lin-1 in renal cell carcinoma and its association with B7-H3.Saeednejad Zanjani L, Vafaei S, Abolhasani M, Fattahi F, **Madjd Z.**Cancer Biomark. 2022;35(3):269-292.
21. RNA-sequencing for transcriptional profiling of whole blood in early stage and metastatic pancreatic cancer patients.Kalantari S, Kazemi B, Roudi R, Zali H, D'Angelo A, Mohamadkhani A, **Madjd Z,** Pourshams A.Cell Biol Int. 2022 Oct 13. doi: 10.1002.
22. Production and characterization of a new specific monoclonal antibody against A-isoform of SALL4: A novel emerging testicular cancer marker. Lakpour N, Ghods R, Sadeghi MR, Ranjbar MM, Abolhasani M, Kiani J, Saliminejad K, Balay-Goli L, Bayat AA, Souri F, **Madjd Z.**Andrologia. 2022 Dec;54(11):e14608
23. Periostin: biology and function in cancerDorafshan S, Razmi M, Safaei S, Gentilin E, **Madjd Z,** Ghods R.Cancer Cell Int. 2022 Oct 12;22(1):315
24. Generation and Characterization of Novel Diagnostic Mouse Monoclonal Antibodies Against Human Estrogen Receptor Alpha and Progesterone Receptor. Hassanzadeh Makoui M, Mobini M, Khoshnoodi J, Judaki MA, Bahadori T, Ahmadi Zare H, Golsaz-Shirazi F, Moradi Tabriz H, **Madjd Z,** Jeddi-Tehrani M, Zarnani AH, Amiri MM, Shokri F.Asian Pac J Cancer Prev. 2022 Sep 1;23(9):2999-3007.
25. Preventive cancer stem cell-based vaccination modulates tumor development in syngeneic colon adenocarcinoma murine model.Eini L, Naseri M, Karimi-Busheri F, Bozorgmehr M, Ghods R, **Madjd Z.**J Cancer Res Clin Oncol. 2022 Aug 30. doi: 10.1007/s00432-022-04303-8

26. Impact of COVID-19 pandemic on screening and diagnosis of patients with prostate cancer: a systematic review protocol. Mostafavi Zadeh SM, Tajik F, Moradi Y, Kiani J, Ghods R, **Madjd Z**. *BMJ Open*. 2022 Aug 26;12(8):e063748. doi: 10.1136/bmjopen-2022-063748
27. Copy Number Variation of Circulating Tumor DNA (ctDNA) Detected Using NIPT in Neoadjuvant Chemotherapy-Treated Ovarian Cancer Patients. Sharbatoghli M, Fattahi F, Aboulkheyr Es H, Akbari A, Akhavan S, Ebrahimi M, Asadi-Lari M, Totonchi M, **Madjd Z**. *Front Genet*. 2022 Jul 22.
28. Oncogenic functions and clinical significances of DCLK1 isoforms in colorectal cancer: a systematic review and meta-analysis. Kalantari E, Razmi M, Tajik F, Asadi-Lari M, Ghods R, **Madjd Z**. *Cancer Cell Int*. 2022 Jun 18;22(1):217.
29. Overexpression of cytoplasmic dynamin 2 is associated with worse outcomes in patients with clear cell renal cell carcinoma. Safaei S, Sajed R, Saeednejad Zanjani L, Rahimi M, Fattahi F, Ensieh Kazemi-Sefat G, Razmi M, Dorafshan S, Eini L, **Madjd Z**, Ghods R. *Cancer Biomark*. 2022 May 30.
30. Upregulation of Ganglioside GD2 Synthase (GD2S), as a New Putative Cancer Stem Cell Marker in Breast Carcinomas. Mansoori M, Mirzaei A, Abdi Rad I, Mahmoodlou R, Mansouri F, Saeednejad Zanjani L, Asadi-Lari Z, **Madjd Z**. *Med J Islam Repub Iran*. 2021 Nov 6;35:148.
31. Co-expression of cancer stem cell markers, SALL4/ALDH1A1, is associated with tumor aggressiveness and poor survival in patients with serous ovarian carcinoma. Sharbatoghli M, Shamshiripour P, Fattahi F, Kalantari E, Habibi Shams Z, Panahi M, Totonchi M, Asadi-Lari Z, **Madjd Z**, Saeednejad Zanjani L. *J Ovarian Res*. 2022 Jan 28;15(1):17.
32. Introduction of an efficient method for placenta decellularization with high potential to preserve ultrastructure and support cell attachment. Sajed R, Zarnani AH, **Madjd Z**, Arefi S, Bolouri MR, Vafaei S, Samadikuchaksaraei A, Gholipourmalekabadi M, Haghhighipour N, Ghods R. *Artif Organs*. 2022 Jan 12. doi: 10.1111/aor.14162. PMID: 35023156
33. Co-expression of cancer-testis antigens of MAGE-A6 and MAGE-A11 is associated with tumor aggressiveness in patients with bladder cancer. Mohsenzadegan M, Razmi M, Vafaei S, Abolhasani M, **Madjd Z**, Saeednejad Zanjani L, Sharifi L. *Sci Rep*. 2022 Jan 12;12(1):599. doi: 10.1038/s41598-021-04510-2. PMID: 35022469
34. Significant co-expression of putative cancer stem cell markers, EpCAM and CD166, correlates with tumor stage and invasive behavior in colorectal cancer. Kalantari E, Taheri T, Fata S, Abolhasani M, Mehrazma M, **Madjd Z**, Asgari M. *World J Surg Oncol*. 2022 Jan 11;20(1):15. doi: 10.1186/s12957-021-02469-y. PMID: 35016698

35. Bioengineering of fibroblast-conditioned Polycaprolactone/Gelatin electrospun scaffold for skin tissue engineering. Yazdanpanah A, **Madjd Z**, Pezeshki-Modaress M, Khosrowpour Z, Farshi P, Eini L, Kiani J, Seifi M, Kundu SC, Ghods R, Gholipourmalekabadi M. *Artif Organs*. 2022 Jan 10. doi: 10.1111/aor.14169. Online ahead of print. PMID: 35006608
36. Cytoplasmic expression of DCLK1-S, a novel DCLK1 isoform, is associated with tumor aggressiveness and worse disease-specific survival in colorectal cancer. Kalantari E, Ghods R, Zanjani LS, Rahimi M, Eini L, Razmi M, Asadi-Lari M, **Madjd Z**. *Cancer Biomark*. 2021 Dec 24. doi: 10.3233/CBM-210330. PMID: 34958000

2021

37. Does GD2 synthase (GD2S) detect cancer stem cells in blood samples of breast carcinomas? Mansoori M, Abdi Rad I, Mirzaei A, Tam KJ, Mohsen Hosseini S, Mahmoodlu R, Mansouri F, Saeednejad Zanjani L, **Madjd Z**. *J Appl Biomed*. 2021 Dec;19(4):181-189. doi: 10.32725/jab.2021.019. 2021 Sep 16. PMID: 34907737
38. Overexpression of melanoma-associated antigen A2 has a clinical significance in embryonal carcinoma and is associated with tumor progression. Saeednejad Zanjani L, Razmi M, Fattahi F, Kalantari E, Abolhasani M, Saki S, **Madjd Z**, Mohsenzadegan M. *J Cancer Res Clin Oncol*. 2021 Nov 27. doi: 10.1007/s00432-021-03859-1. Online ahead of print. PMID: 34837545
39. Relationship Between Low Expressions of tRNA-Derived Fragments with Metastatic Behavior of Colorectal Cancer. Sahlolbei M, Fattahi F, Vafaei S, Rajabzadeh R, Shiralipour A, **Madjd Z**, Kiani J. *J Gastrointest Cancer*. 2021 Nov 26. doi: 10.1007/s12029-021-00773-0. Online ahead of print. PMID: 34837147
40. An Integrative Analysis of The Micro-RNAs Contributing in Stemness, Metastasis and B-Raf Pathways in Malignant Melanoma and Melanoma Stem Cell. Sahranavardfard P, **Madjd Z**, Emami Razavi AN, Ghanadan AR, Firouzi J, Khosravani P, Ghavami S, Ebrahimie E, Ebrahimi M. *Cell J*. 2021 Aug;23(3):261-272. doi: 10.22074/cellj.2021.7311. Epub 2021 Jul 17. PMID: 34308569
41. Highly Photoluminescent Nitrogen- and Zinc-Doped Carbon Dots for Efficient Delivery of CRISPR/Cas9 and mRNA. Hasanzadeh A, Radmanesh F, Hosseini ES, Hashemzadeh I, Kiani J, Nourizadeh H, Naseri M, Fatahi Y, Chegini F, **Madjd Z**, Beyzavi A, Kowalski PS, Karimi M. *Bioconjug Chem*. 2021 Aug 18;32(8):1875-1887. doi: 10.1021/acs.bioconjchem.1c00309. 2021 Jul
42. High expression of DNA damage-inducible transcript 4 (DDIT4) is associated with advanced pathological features in the patients with colorectal cancer. Fattahi F, Saeednejad Zanjani L, Habibi Shams Z, Kiani J, Mehrzama M, Najafi M, **Madjd Z**. *Sci Rep*. 2021 Jul 1;11(1):13626.

43. Increased cytoplasmic expression of DLL4 is associated with favorable prognosis in colorectal cancer. Naseri M, Saeednejad Zanjani L, Vafaei S, Gheytauchi E, Abolhasani M, Bozorgmehr M, Ranaei Pirmardan E, Ghods R, **Madjd Z**. *Future Oncol*. 2021 Jun 22.
44. Overexpression of DDIT4 and TPTEP1 are associated with metastasis and advanced stages in colorectal cancer patients: a study utilizing bioinformatics prediction and experimental validation. Fattahi F, Kiani J, Alemrajabi M, Soroush A, Naseri M, Najafi M, **Madjd Z**. *Cancer Cell Int*. 2021 Jun 9;21(1):303. doi: 10.1186/s12935-021-02002-x
45. Expression profiling of RTL1 in human breast cancer tissues and cell lines. Mahmoudi AR, Ghods R, **Madjd Z**, Abolhasani M, Zanjani LS, Safaei M, Goli LB, Vafaei S, Katouzian L, Soltanghoraei H, Shekarabi M, Zarnani AH. *Exp Mol Pathol*. 2021 Jun 1:104654. doi: 10.1016/j.yexmp.2021.104654
46. SMAD4 Expression in Renal Cell Carcinomas Correlates With a Stem-Cell Phenotype and Poor Clinical Outcomes. Rasti A, **Madjd Z**, Saeednejad Zanjani L, Babashah S, Abolhasani M, Asgari M, Mehrazma M. *Front Oncol*. 2021 May 3;11:581172. doi: 10.3389/fonc.2021.581172.
47. Morphological and molecular characteristics of spheroid formation in HT-29 and Caco-2 colorectal cancer cell lines. Gheytauchi E, Naseri M, Karimi-Busheri F, Atyabi F, Mirsharif ES, Bozorgmehr M, Ghods R, **Madjd Z**. *Cancer Cell Int*. 2021 Apr 13;21(1):204. doi: 10.1186/s12935-021-01898-9.
48. Expressions of TWIST1 and CD105 markers in colorectal cancer patients and their association with metastatic potential and prognosis. Fattahi F, Saeednejad Zanjani L, Vafaei S, Habibi Shams Z, Kiani J, Naseri M, Gheytauchi E, **Madjd Z**. *Diagn Pathol*. 2021 Mar 22;16(1):26. doi: 10.1186/s13000-021-01088-1.
49. Nuclear overexpression levels of MAGE-A3 predict poor prognosis in patients with prostate cancer. Khalvandi A, Abolhasani M, **Madjd Z**, Shekarabi M, Kourosh-Arami M, Mohsenzadegan M. *APMIS*. 2021 Jun;129(6):291-303. doi: 10.1111/apm.13132. Epub 2021 Apr 13.
50. Clinical and prognostic significances of cancer stem cell markers in gastric cancer patients: a systematic review and meta-analysis. Razmi M, Ghods R, Vafaei S, Sahlolbei M, Saeednejad Zanjani L, **Madjd Z**. *Cancer Cell Int*. 2021 Feb 27;21(1):139. doi: 10.1186/s12935-021-01840-z. PMID: 33639931
51. Dendritic cells loaded with exosomes derived from cancer stem cell-enriched spheroids as a potential immunotherapeutic option. Naseri M, Zöller M, Hadjati J, Ghods R, Ranaei Pirmardan E, Kiani J, Eini L, Bozorgmehr M, **Madjd Z**. *J Cell Mol Med*. 2021 Apr;25(7):3312-3326. doi: 10.1111/jcmm.16401. Epub 2021 Feb 25. PMID: 33634564

52. High expression of tumor susceptibility gene 101 (TSG101) is associated with more aggressive behavior in colorectal carcinoma. Gheytnchi E, Saeednejad Zanjani L, Ghods R, Abolhasani M, Shahin M, Vafaei S, Naseri M, Fattahi F, **Madjd Z.** *J Cancer Res Clin Oncol.* 2021 Jun;147(6):1631-1646. doi: 10.1007/s00432-021-03561-2. 2021 Feb 22.
53. Potential biomarkers for testicular germ cell tumour: Risk assessment, diagnostic, prognostic and monitoring of recurrence. Lakpour N, Saliminejad K, Ghods R, Reza Sadeghi M, Pilatz A, Khosravi F, **Madjd Z.** *Andrologia.* 2021 May;53(4):e13998. doi: 10.1111/and.13998. 2021 Feb 3. Review.
54. Clinicopathological Significance of Tumor Stem Cell Markers ALDH1 and CD133 in Colorectal Carcinoma. Rezaee M, Gheytnchi E, **Madjd Z,** Mehrazma M. *Iran J Pathol.* 2021

2020

55. Dynamic Signature of tRNA-Derived Small RNAs in Cancer Pathogenesis as a Promising Valuable Approach. Vafaei S, Fattahi F, Sahlolbei M, Kiani J, Yazdanpanah A, **Madjd Z.** *Crit Rev Eukaryot Gene Expr.* 2020;30(5):391-410. doi: 10.1615/CritRevEukaryotGeneExpr.2020035372.PMID: 33389877.
56. Exosomes derived from miR-34a-overexpressing mesenchymal stem cells inhibit in vitro tumor growth: A new approach for drug delivery Vakhshiteh F, Rahmani S, Ostad SN, **Madjd Z,** Dinarvand R, Atyabi F. *Life Sci.* 2020 Dec 9;266:118871. doi: 10.1016/j.lfs.2020.118871.
57. Overexpression and translocation of dynamin 2 promotes tumor aggressiveness in breast carcinomas. Sajed R, Saeednejad Zanjani L, Rahimi M, Mansoori M, Zarnani AH, **Madjd Z,** Ghods R. *EXCLI J.* 2020 Oct 29;19:1423-1435. doi: 10.17179/excli2020-2762
58. Discovery of a potential biomarker for immunotherapy of melanoma: PLAC1 as an emerging target. Mahmoudi AR, Ghods R, Rakhshan A, **Madjd Z,** Bolouri MR, Mahmoudian J, Rahdan S, Shokri MR, Dorafshan S, Shekarabi M, Zarnani AH. *Immunopharmacol Immunotoxicol.* 2020 Dec;42(6):604-613
59. Low expression of Talin1 is associated with advanced pathological features in colorectal cancer patients. Vafaei S, Saeednejad Zanjani L, Habibi Shams Z, Naseri M, Fattahi F, Gheytnchi E, Alemrajabi M, Ebrahimi M, **Madjd Z.** *Sci Rep.* 2020 Oct 20;10(1):17786.
60. Prediction of the treatment response in ovarian cancer: a ctDNA approach. Sharbatoghli M, Vafaei S, Aboulkheyr Es H, Asadi-Lari M, Totonchi M, **Madjd Z.** *J Ovarian Res.* 2020 Oct 19;13(1):124.
61. Highly Efficient Generation of Transgenically Augmented CAR NK Cells Overexpressing CXCR4. Jamali A, Hadjati J, **Madjd Z,** Mirzaei HR, Thalheimer FB, Agarwal S, Bonig H, Ullrich E, Hartmann J. *Front Immunol.* 2020 Aug
62. DCLK1, a promising colorectal cancer stem cell marker, regulates tumor progression and invasion through miR-137 and miR-15a dependent manner. Razi

- S, Sadeghi A, Asadi-Lari Z, Tam KJ, Kalantari E, **Madjd Z**. Clin Exp Med. 2020 Sep 23.
63. Expression patterns and clinical significance of the potential cancer stem cell markers OCT4 and NANOG in colorectal cancer patients. R Roudi, M Barodabi, Z Madjd, G Roviello, SP Corona, M Panahei. Molecular & Cellular Oncology, Sep2020
 64. Tissue tRNA-Derived Fragments (tRFs) as Potential Candidates Correlate with Invasiveness in Colorectal Carcinomas. F Fattahi, S Vafaei, R Rajabzadeh, Z Madjd, J Kiani
 65. Nuclear overexpression levels of MAGE-A3 predict poor prognosis in patients with prostate cancer. M Abolhasani, Z Madjd, M Shekarabi, MK Arami, M Mohsenzadegan
 66. Dynamic Signature of tRNA-Derived small RNAs in Cancer Pathogenesis as a Promising Valuable Approach. S Vafaei, F Fattahi, M Sahlolbei, Z Madjd, A Yazdanpanah, J Kiani
 67. Tumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy .Naseri, M., Bozorgmehr, M., Zoller, M., Ranaei Pirmardan, E., Madjd, Z., Oncoimmunology, 9(1),1779991 .2020
 68. Peptide-conjugated liposomes for targeted miR-34a delivery to suppress breast cancer and cancer stem-like population Vakhshiteh, F., Khabazian, E., Atyabi, F., (...), Madjd, Z., Dinarvand, R. Journal of Drug Delivery Science and Technology, 57,101687
 69. Low level expression of human telomerase reverse transcriptase predicts cancer-related death and progression in embryonal carcinoma. Shahin M, Saeednejad Zanjani L, Abolhasani M, Rahbar M, Asgari M, **Madjd Z**. J Cancer Res Clin Oncol. 2020 Jul 17. doi: 10.1007/s00432-020-03319-2.
 70. Potential theranostics of circulating tumor cells and tumor-derived exosomes application in colorectal cancer. Vafaei S, Roudi R, **Madjd Z**, Aref AR, Ebrahimi M. Cancer Cell Int. 2020 Jul 6;20:288.
 71. Control of Hyperglycemia Using Differentiated and Undifferentiated Mesenchymal Stem Cells in Rats with Type 1 Diabetes. Aali E, Madjd Z, Tekiyehmaroof N, Sharifi AM. Cells Tissues Organs. 2020 Jul 7:1-13.
 72. A comparative study of long interspersed element-1 protein immunoreactivity in cutaneous malignancies. Zolfaghari MA, Karimi A, Kalantari E, Korourian A, Ghanadan A, Kamyab K, Esmaili N, Emami Razavi AN, **Madjd Z**. BMC Cancer. 2020 Jun 17;20(1):567. doi: 10.1186/s12885-020-07050-6
 73. Evaluation of targetable biomarkers for chimeric antigen receptor T-cell (CAR-T) in the treatment of pancreatic cancer: a systematic review and meta-analysis of preclinical studies. Sahlolbei M, Dehghani M, Kheiri Yeghane Azar B, Vafaei S, Roviello G, D'Angelo A, **Madjd Z**, Kiani J. Int Rev Immunol. 2020 Jun 16:1-10. doi: 10.1080/08830185.2020.
 74. Local eosinophils are associated with increased IgA subclass levels in the sinonasal mucosa of chronic rhinosinusitis with polyp patients. Aazami H, Seif F, Ghalehbaghi B, Babaheidarian P, Mohebbi A, Ahmadi A, Khoshmirsafa M, Ghalehbaghi S, Behnam B, Entezami KZ, **Madjd Z**, Falak R. Allergy Asthma Clin Immunol. 2020 Apr 25;16:30. doi: 10.1186/s13223-020-00428-y

75. Cytoplasmic expression of B7-H3 and membranous EpCAM expression are associated with higher grade and survival outcomes in patients with clear cell renal cell carcinoma. Saeednejad Zanjani L, **Madjd Z**, Axcrona U, Abolhasani M, Rasti A, Asgari M, Fodstad Ø, Andersson Y. *Ann Diagn Pathol*. 2020 Feb 25;46:151483. 2020

2019

76. Spheroid-derived cells from renal adenocarcinoma have low telomerase activity and high stem-like and invasive characteristics. Saeednejad L, **Madjd Z**, Rasti A, Asgari M, Abolhasani M, Tam K, Roudi R, Mælandsmo G, Fodstad Ø, Andersson Y. *Frontiers in Oncology*, Dec 2019

77. Suppression of nicotinamide phosphoribosyltransferase expression by miR-154 reduces the viability of breast cancer cells and increases their susceptibility to doxorubicin. Bolandghamat Pour Z, Nourbakhsh M, Mousavizadeh K, **Madjd Z**, Ghorbanhosseini SS, Abdolvahabi Z, Hesari Z, Ezzati Mobasser S. *BMC Cancer*. 2019 Nov 1;19(1):1027.

78. Enrichment of Up-regulated and Down-regulated Gene Clusters using Gene Ontology, miRNAs and lncRNAs in Colorectal Cancer. Fattahi F, Kiani J, Khosravi M, Vafaei S, Mohammadi A, **Madjd Z**, Najafi M. *Comb Chem High Throughput Screen*. 2019 Oct 10.

79. Up-regulation of miR-381 inhibits NAD⁺ salvage pathway and promotes apoptosis in breast cancer cells. Bolandghamat Pour Z, Nourbakhsh M, Mousavizadeh K, **Madjd Z**, Ghorbanhosseini SS, Abdolvahabi Z, Hesari Z, Mobaser SE. *EXCLI J*. 2019 Aug 27;18:683-696.

80. Primary colonospheres maintain stem cell-like key features after cryopreservation. Eini L, Naseri M, Karimi-Busheri F, Bozorgmehr M, Ghods R, **Madjd Z**. *J Cell Physiol*. 2019 Oct 2.

81. Common molecular markers between circulating tumor cells and blood exosomes in colorectal cancer: a systematic and analytical review. Vafaei S, Fattahi F, Ebrahimi M, Janani L, Shariftabrizi A, **Madjd Z**. *Cancer Manag Res*. 2019 Sep 25;11:8669-8698.

82. An evaluation of the effect of bortezomib on radiation-induced urinary bladder dysfunction. Sarsarshahi S, **Madjd Z**, Bozsaky E, Kowaliuk J, Kuess P, Ghahremani MH, Doerr W. *Strahlenther Onkol*. 2019 Oct;195(10):934-939. 2019 Jul 30.

83. Co-expression of TLR-9 and MMP-13 is associated with the degree of tumour differentiation in prostate cancer. Kalantari E, Abolhasani M, Roudi R, Farajollahi MM, Farhad S, **Madjd Z**, Askarian-Amiri S, Mohsenzadegan M. *Int J Exp Pathol*. 2019 Apr;100(2):123-132.

84. High GD2 expression defines breast cancer cells with enhanced invasiveness. Mansoori M, Roudi R, Abbasi A, Abolhasani M, Rad IA, Shariftabrizi A, **Madjd Z**. *Exp Mol Pathol*. 2019 May.

85. Increased expression of DCLK1, a novel putative CSC maker, is associated with tumor aggressiveness and worse disease-specific survival in patients with bladder carcinomas. Shafiei S, Kalantari E, Zanjani LS, Abolhasani M, Asadi Lari MH, **Madjd Z**. *Exp Mol Pathol*. 2019 Apr 24.
86. CD44 epithelial isoform inversely associates with invasive characteristics of colorectal cancer. Sadeghi A, Roudi R, Mirzaei A, Mirzaei AZ, **Madjd Z**, Abolhasani M. *Biomark Med*. 2019 Apr 3.
87. Induction of miR-31 causes increased sensitivity to 5-FU and decreased migration and cell invasion in gastric adenocarcinoma, A Korourian, Z Madjd, R Roudi, A Shariftabrizi, M Soleimani, *Bratislavske lekarske listy*, 2019
88. In vitro cytotoxicity of folate-silica-gold nanorods on mouse acute lymphoblastic leukemia and spermatogonial cells, N Eslahi, A Shakeri-Zadeh, K Ashtari, V Pirhajati-Mahabadi, Z Madjd, *Cell J (Yakhteh)*, 21 (1), 2019
89. Human telomerase reverse transcriptase protein expression predicts tumor aggressiveness and survival in patients with clear cell renal cell carcinoma. Leili Saeednejad Zanjani, Zahra Madjd, Maryam Abolhasani, Ahmad Shariftabrizi, Arezoo Rasti, Øystein Fodstad, Mojgan Asgari, 2019. *Pathology*

2018

90. Co-expression of Cancer Stem Cell Markers OCT4 and NANOG Predicts Poor Prognosis in Renal Cell Carcinomas. Arezoo Rasti, Mitra Mehrazma, Zahra Madjd*, Maryam Abolhasani , Leili Saeednejad Zanjani, Mojgan Asgari. *Scientific reports*, August 2018
91. 3D Protein-Based Bilayer Artificial Skin for Guided Scarless Healing of 3rd degree Burn Wounds In vivo. Gholipourmalekabadi M, Seifalian AM, Urbanska AM, Omrani MD, Hardy JG, **Madjd Z**, Hashemi SM, Ghanbarian H, Brouki Milan P, Mozafari M, Reis RL, Kundu SC, Samadikuchaksaraei A. *Biomacromolecules*. 2018 Jul 9;19(7):2409-2422.
92. Increased expression of CD44 is associated with more aggressive behavior in clear cell renal cell carcinoma. Zanjani LS, **Madjd Z**, Abolhasani M, Rasti A, Fodstad O, Andersson Y, Asgari M. *Biomark Med*. 2018 Jan

2017

93. Expression of CD105 cancer stem cell marker in three subtypes of renal cell carcinoma. Zanjani LS, **Madjd Z**, Abolhasani M, Shariftabrizi A, Rasti A, Asgari M. *Cancer Biomark*. 2017 Dec 20
94. Circulating cancer stem cell markers in breast carcinomas: a systematic review protocol. Mansoori M, **Madjd Z**, Janani L, Rasti A. *Syst Rev*. 2017 Dec
95. Cytoplasmic expression of Twist1, an EMT-related transcription factor, is associated with higher grades renal cell carcinomas and worse progression-free survival in clear cell renal cell carcinoma" , Rasti A , **Madjd Z** , Abolhasani M,

- Mehrazma M , Janani L , Saeednejad Zanjani L · Asgari A, Clinical and Experimental Medicine, Dec 2017
96. Exosomal microRNAs as potential circulating biomarkers in gastrointestinal tract cancers: a systematic review protocol. Gheytaichi E, **Madjd Z**, Janani L, Rasti A, Ghods R, Atyabi F, Lari MHA, Babashah S. Syst Rev. 2017 Nov 17;6(1):228.
 97. Cytoplasmic expression of CD133 stemness marker is associated with tumor aggressiveness in clear cell renal cell carcinoma. Saeednejad Zanjani L, Madjd Z, Abolhasani M, Andersson Y, Rasti A, Sharifabrizi A, Asgari M. Exp Mol Pathol. 2017 Oct 16;103(2):218-228.
 98. Lgr5High/DCLK1High phenotype is more common in early stage and intestinal subtypes of gastric carcinomas. Elham Kalantaria, Mohammad H. Asadi Larib, Raheleh Roudia, Alireza Korourianc and **Zahra Madjd**. Cancer Biomarkers, 2017 Oct
 99. MicroRNA-31 inhibits RhoA-mediated tumor invasion and chemotherapy resistance in MKN-45 gastric adenocarcinoma cells. Korourian A, Roudi R, Sharifabrizi A, **Madjd Z**. Exp Biol Med (Maywood). 2017 Sep
 100. Cancer Stem Cell Research in Iran: Potentials and Challenges, Raheleh Roudi, Marzieh Ebrahimi, Ahmad Sharifabrizi, **Zahra Madjd** , Future Oncology , 2017 August
 101. Cancer stem cell's potential clinical implications, Mirzaei, A., **Madjd, Z.**, Kadijani, A.A., (...), Akbari, A., Tavoosidana, G., Iranian Journal of Cancer Prevention, 2017
 102. Co-Expression of Putative Cancer Stem Cell Markers CD44 and CD133 in Prostate Carcinomas, : Pathology oncology research, Kalantari E, Asgari M, Nikpanah S, Salarieh N, Asadi Lari MH, **Madjd Z**, 2017
 103. Possible involvement of CREB/BDNF signaling pathway in neuroprotective effects of topiramate against methylphenidate induced apoptosis, oxidative stress and inflammation in isolated hippocampus of rats: Molecular, biochemical and histological evidences Motaghinejad M, Motevalian M, Babalouei F, Abdollahi M, Heidari M, **Madjd Z**.Brain Res Bull. 2017 May 24;132:82-98
 104. Topiramate Confers Neuroprotection Against Methylphenidate-Induced Neurodegeneration in Dentate Gyrus and CA1 Regions of Hippocampus via CREB/BDNF Pathway in Rats, Neurotoxicity research, Motaghinejad M, Motevalian M, Abdollahi M, Heidari M, Madjd Z. 2017
 105. Reduced expression of CXCR4, a novel renal cancer stem cell marker, is associated with high-grade renal cell carcinoma.A Rasti, M Abolhasani, LS Zanjani, M Asgari, M Mehrazma, Z Madjd. Journal of Cancer Research and Clinical Oncology, 2017, 1-10

106. Evaluation of circulating cellular DCLK1 protein, as the most promising colorectal cancer stem cell marker, using immunoassay based methods. A Mirzaei, Z Madjd, AA Kadijani, M Tavakoli-Yaraki, MH Modarresi, *Cancer Biomarkers*, 2016, page 1-11
107. Differential role of Wnt signaling and base excision repair pathways in gastric adenocarcinoma aggressiveness. Korourian A, Roudi R, Shariftabrizi A, Kalantari E, Sotoodeh K, **Madjd Z**. *Clin Exp Med*. 2016 Dec 1
108. Coenzyme Q10 Ameliorates Trimethyltin Chloride Neurotoxicity in Experimental Model of Injury in Dentate Gyrus of Hippocampus: A Histopathological and Behavioral Study. MH Sakhaie, M Soleimani, V Pirhajati, SS Asl, Z Madjd, M Mehdizadeh. *Iranian Red Crescent Medical Journal*, 2016
109. Probiotic feeding affects T cell populations in blood and lymphoid organs in chickens. Asgari F, **Madjd Z**, Falak R, Bahar MA, Nasrabadi MH, Raiani M, Shekarabi M. *Benef Microbes*. 2016 Jun 28:1-8
110. Expression of CD133 cancer stem cell marker in melanoma: a systematic review and meta-analysis. **Zahra Madjd**, Elham Erfani, Elmira Gheytnchi, Maziar Moradi-Lakeh, Ahmad Shariftabrizi, Mohsen Asadi-Lari. *Int J Biol Markers* 2016.
111. Evidence for embryonic stem-like signature and epithelial-mesenchymal transition features in the spheroid cells derived from lung adenocarcinoma. Roudi R, Madjd Z, Ebrahimi M, Najafi A, Korourian A, Shariftabrizi A, Samadikuchaksaraei A. *Tumour Biol*. 2016 Apr 5.
112. Expression of Cancer Stem Cell Markers OCT4 and CD133 in Transitional Cell Carcinomas. Sedaghat S, Gheytnchi E, Asgari M, Roudi R, Keymoosi H, **Madjd Z**. *Appl Immunohistochem Mol Morphol*. 2016 Mar 3.
113. Accuracy of c-KIT in Lung Cancer Prognosis; a Systematic Review Protocol". Roudi R, Kalantari E, Keshtkar A, **Madjd Z**. *Asian Pac J Cancer Prev*. 2016;17(2):863-6.
114. Increased Expression of ALDH1A1 in Prostate Cancer is Correlated With Tumor Aggressiveness: A Tissue Microarray Study of Iranian Patients. Kalantari E, Saadi FH, Asgari M, Shariftabrizi A, Roudi R, Madjd Z. *Appl Immunohistochem Mol Morphol*. 2016 Feb 18.
115. Diagnostic and prognostic accuracy of miR-21 in renal cell carcinoma: a systematic review protocol. Rasti A, Mehrzama M, **Madjd Z**, Keshtkar AA, Roudi R, Babashah S. *BMJ Open*. 2016 Jan
116. Impaired Memory and Evidence of Histopathology in CA1 Pyramidal Neurons through Injection of A β 1-42 Peptides into the Frontal Cortices of Rat. Eslamizade MJ, **Madjd Z**, Rasoolijazi H, Saffarzadeh F, Pirhajati V, Aligholi H, Janahmadi M, Mehdizadeh M. *Basic Clin Neurosci*. 2016 Jan;7(1):31-41.
117. Evaluation of anaplastic lymphoma kinase (ALK) expression in nonsmall cell lung cancer; a tissue microarray analysis. Raheleh Roudi, Gholamreza Haji, **Zahra Madjd**, Ahmad Shariftabrizi, Mitra **Mehrazma**. *Journal of Cancer Research and Therapeutic*. 2016

2015

118. Comparative gene-expression profiling of CD133⁺ and CD133⁻ D10 melanoma cells. Roudi R, Ebrahimi M, Sabet MN, Najafi A, Nourani MR, Fomeshi MR, Samadikuchaksaraei A, Shariftabrizi A, **Madjd Z**. *Future Oncol* (IF=2.5). 2015 Aug 19:1-11 (Corresponding author)
119. A new insight into cancer stem cell markers: Could local and circulating cancer stem cell markers correlate in colorectal cancer? Mirzaei A, Tavosidana G, Rad AA, Rezaei F, Tavakoli-Yaraki M, Kadijani AA, Khalili E, **Madjd Z**. *Tumour Biol*. 2015 Sep 17
120. Comparative expression analysis of putative cancer stem cell markers CD44 and ALDH1A1 in various skin cancer subtypes, Elham Erfani¹, Raheleh Roudi, Azadeh Rakhshan, Mehrdad Nasrollahzadeh Sabet, Ahmad Shariftabrizi, Zahra Madjd, *Int J Biomedical Markers*.2015. (Corresponding author)
121. A Simple, Rapid, and Efficient Method for Isolating Mesenchymal Stem Cells from the Entire Umbilical Cord. Dehkordi MB, **Madjd Z**, Chaleshtori MH, Meshkani R, Nikfarjam L, Kajbafzadeh A. *Cell Transplant*. 2015 Aug 12(Corresponding author)
122. PI3K/Akt inhibition and down-regulation of BCRP re-sensitize MCF7 breast cancer cell line to mitoxantrone chemotherapy. Komeili-Movahhed T, Fouladdel S, Barzegar E, Atashpour S, Hossein Ghahremani M, Nasser Ostad S, **Madjd Z**, Azizi E. *Iran J Basic Med Sci*. 2015 May;18(5):472-7.
123. Differential expression of cancer stem cell markers ALDH1 and CD133 in various lung cancer subtypes, Raheleh Roudi, Alireza Korourian, Ahmad Shariftabrizi, and **Zahra Madjd**. *Cancer Invest* (IF=2.06). 2015 Jun 5. (corresponding Author)
124. Study of NGEF expression in androgen sensitive prostate cancer cells: A potential target for immunotherapy. Mohsenzadegan M, Tajik N, **Madjd Z**, Shekarabi M, Farajollahi MM. *Med J Islam Repub Iran*. 2015 Jan 13;29:159
125. Study of NGEF expression pattern in cancerous tissues provides novel insights into prognostic marker in prostate cancer. Mohsenzadegan M, Shekarabi M, **Madjd Z**, Asgari M, Abolhasani M, Tajik N, Farajollahi MM. *Biomark Med* (IF=2.5). 2015; 9(4):391-401.
126. Effect of Copper Sulfate on Expression of Endogenous L1 Retrotransposons in HepG2 Cells (Hepatocellular Carcinoma). Karimi A, Majidzadeh-A K, **Madjd Z**, Akbari A, Habibi L, Akrami SM. *Biol Trace Elem Res* (IF=1.5). 2015 Jun;165(2):131-4.
127. Upregulation of circulating cancer stem cell marker, DCLK1 but not Lgr5, in chemoradiotherapy-treated colorectal cancer patients. Mirzaei A, Tavosidana G, Modarressi MH, Rad AA, Fazeli MS, Shirkoohi R, Tavakoli-Yaraki M, **Madjd Z**. *Tumour Biol*. (IF=2.8) 2015 Jan 29. (Corresponding author)

2014

128. Tissue microarrays, a revolution in pathology research, Elham Kalantari , **Zahra Madjd**, BCCR, 2014. (Corresponding author).
129. Prognostic relevance of putative cancer stem cell marker, CD44 in different histological sub-types of lung cancer. Raheleh Roudi, **Zahra Madjd**, Alireza Korourian, Mitra Mehrazma, Ahmad Shariftabrizi, SaadatMolanae. *Cancer Biomarkers* 14 (2014) 457–467 (IF= 1.18) (Corresponding author).
130. Co-Expression of Putative Cancer Stem Cell Markers, CD133 and Nestin, in Skin Tumors. Mehrdad Nasrollahzadeh Sabet , Azadeh Rakhshan , Elham Erfani , **Zahra Madjd**, *Asian Pac J Cancer Prev*, 15 (19), 8161-8169. (IF= 1.27)
131. Tissue Microarray-based investigation PLAC1 expression in Prostate Carcinoma. Roya Ghods, Mohammad Hossein Ghahremani, **Zahra Madjd** , Mojgan Asgari Maryam Abolhasani, Sanaz Tavassoli , Ahmad Reza Mahmoudi, Mahmood Jeddi-Tehrani, Maryam Darzi, Amir-Hassan Zarnani, *Cancer Immunology Immunotherapy* (IF=3.94), 2014 Sep 4.
132. A comparative study of mesenchymal stem cell transplantation with its paracrine effect on control of hyperglycemia in type 1 diabetic rats. Aali E, Mirzamohammadi S, Ghaznavi H, **Madjd Z**, Larijani B, Rayegan S, Sharifi AM.J *Diabetes Metab Disord*. 2014 Aug 11;13(1):76. doi: 10.1186/2251-6581-13-76.
133. Exposure of hepatocellular carcinoma cells to low-level As₂O₃ causes an extra toxicity pathway via L1 retrotransposition induction. Karimi A, **Madjd Z**, Habibi L, Akrami SM. *Toxicol Lett*(IF=3.5). 2014 Jun 21; 229(1):111-117.
134. Evaluating the Extent of LINE-1 Mobility Following Exposure to Heavy Metals in HepG2 Cells. Karimi A, **Madjd Z**, Habibi L, Akrami SM. *Biol Trace Elem Res* (IF=1.5). 2014 Jul;160 (1):143-51. 2014 Jun 5.
135. Expression of Ki-67, p53 and VEGF in pediatric neuroblastoma. Gheytauchi E, Mehrazma M, **Madjd Z**. *Asian Pac J Cancer Prev* (IF=1.27). 2014; 15 (7): 3065-70.
136. ALDH1 in combination with CD44 as putative cancer stem cell markers are correlated with poor prognosis in urothelial carcinoma of the urinary bladder. Keymoosi H, Gheytauchi E, Asgari M, Shariftabrizi A, **Madjd Z**. *Asian Pac J Cancer Prevention* (IF=1.27). 2014; 15(5):2013-20. (Corresponding author)
137. Expression of EMSY, a novel BRCA2-link protein, is associated with lymph node metastasis and increased tumour size in breast carcinomas. Zahra Madjd, Mohammad E. Akbari; Amir Hassan Zarnani, Maryam Khayam zadeh, Elham Kalantari, Nazanin Mojtavavi., *Asian Pacific J Can Prevention* (IF=1.27), Volume 14, Issue 4 (Corresponding author)

2013

138. The expression of p53 and MDM4 in oral, laryngeal and cutaneous squamous cell carcinoma: A comparative study by tissue microarray Sami Jabar, Seta Sarkis, **Zahra Madjd**, Elham Kalantari, *European Scientific Journal*, December 2013
139. CD44 and CD24 markers cannot act as cancer stem cell markers in human lung adenocarcinoma cell line A549. Raheleh Roudi. Marzieh

- Ebrahimi, Ali Samadikuchaksaraei, **Zahra Madjd**. CELLULAR & MOLECULAR BIOLOGY LETTERS (IF=1.9), 13 Dec 2013. (Corresponding author)
140. Evaluation of methylation of MGMT (O⁶-methyl guanine methyltransferase) gene promoter by Methylation Specific-PCR in meningiomas with atypical features and its comparison between tumor grades I, II, and III, Leila Larijani, **Zahra Madjd** et al, accepted to be included in Asian Pacific J Can Prevention (IF=1.27), Volume 14, Issue 2.
141. Expression of prostate stem cell antigen (PSCA) in prostate cancer; a tissue microarray study of Iranian patients. Jaleh Taeb, Mojgan Asgari, Maryam Abolhasani, Mohammad M Farajollahi, **Zahra Madjd**. Pathol Res Pract (IF=1.4). 2013 Oct 11 (Corresponding author)
142. Reduced expression of NGEP is associated with high grade prostate cancers: a tissue microarray analysis. Monireh Mohsenzadegan , **Zahra Madjd**, Mojgan Asgari, Maryam Abolhasani, Mehdi Shekarabi , Jaleh Taeb, Ahmad Shariftabrizi, Cancer Immunology Immunotherapy, Cancer Immunology Immunotherapy (IF=3.94). 2013 Oct; 62 (10) (Corresponding author)
143. Application of Stem Cells in Targeted Therapy of Breast Cancer: A Systematic Review. **Madjd Z**, Gheytaichi E, Erfani E, Asadi-Lari M. Asian Pac J Cancer Prev. 2013;14(5):2789-2800. (Corresponding Author)
144. Chronic Ritalin Administration during Adulthood Increases Serotonin Pool in Rat Medial Frontal Cortex. Daniali S, Nahavandi A, **Madjd Z**, Shahbazi A, Niknazar S, Shahbazzadeh D. Iran Biomed J. 2013 Jul;17(3):134-9.

2012

145. Expression of stem cell markers, CD133 and CD44 in pediatric solid tumours, a study using Tissue microarray. Mitra Mehrazma, Zahra Madjd, Elham Kalantari, Mahshid Panahi, Alireza Hendi. Fetal Pediatr Pathol. 2013 Jun; 32(3):192-204. 2012
146. High expression of stem cell marker ALDH1 is associated with mutated BRCA1 in invasive breast carcinomas, **Zahra Madjd**, Babak Ramezani , Mohsen Asadi Lari, Saadat Molanae, Asian Pac J Cancer Prev. 2012;13(6):2973-8
147. Do clinical and demographic features of patients with upper-gastrointestinal cancer affect their health-related quality of life? Ali Esmaili-Hesari, Fatemeh Homai, Abbas Motevallian, **Zahra Madjd**, Masoud Solaymani-Dodaran, Mohsen Asadi-Lari. Int J Prev Med. 2012 Nov; 3(11):783-90.

148. The clinicopathologic association of c-MET overexpression in Iranian gastric carcinomas; an immunohistochemical study of tissue microarrays. Sotoudeh K, Hashemi F, **Madjd Z**, Sadeghipour A, Molanaei S, Kalantari E. *Diagn Pathol.* 2012 May 28; 7:57.
149. Apelin-13 Protects the Brain Against Ischemic Reperfusion Injury and Cerebral Edema in a Transient Model of Focal Cerebral Ischemia. Khaksari M, Aboutaleb N, Nasirinezhad F, Vakili A, **Madjd Z**. *J Mol Neurosci.* 2012 Sep;48(1):201-8.

2011

150. Occult Hepatitis C Virus Infection in Iranian Patients with Chronic Liver Disease with Unknown Etiology, Farah Bokharaei Salim, Hossein keyvani, Seyed Moayed Alavian, Seyed Hamid Reza Monavari, **Zahra Madjd**, Mohsen Nasiri Tousi, Amir Houshang Alizadeh. *Journal of Medical Virology*, 2011, June
151. Neuroprotective Effect of Exogenous Melatonin on Dopaminergic Neurons of the Substantia Nigra in Ovariectomized Rats. Fereshteh Mehraein, Reza Talebi, Behnamedin Jameie, Mohammad Taghi Joghataie and Zahra Madjd, *Iranian Biomedical Journal* 15 (1 & 2): 44-50 (April & January 2011).
152. BRCA1 protein expression level and CD44+ phenotype in breast cancer patients. **Zahra Madjd**, Adel Karimi, Saadat Molanae, Mohsen Asadi-Lari. *CELL JOURNAL (Yakhteh)*, Vol 13, No 3, Autumn 2011 (Corresponding Author)
153. Immunohistochemical localization of endothelial nitric oxide synthase in testicular cells of men with non- obstructive azospermia, Khadijeh Foghi , Marefat Ghaffari Novin., **Zahra Madjd**, Tohid Najafi., Mohammad Hasan Heidari., Abouzar Rostampour Yasoori. *Iranian Journal of Reproductive Medicine* Vol.9. No.4. pp:277-280, Autumn 2011.
154. Expression of BRCA1 Protein in Invasive and In Situ Carcinomas and its Relation with Marker of Breast Cancer Stem Cells (CD44) and Prognostic Factors in Breast Cancer Patients. **Madjd Z**, Karimi A, Hashemi F, Molanae S, Razi *Journal of Medical Sciences* Vol. 17, No. 80 & 81, Feb/Mar 2010-2011 (In Persian)
155. The immunohistochemical assessment of ALDH1 activity in breast cancer and it's correlation with pathologic features. Babak Ramezani, Zahra Madjd, Maryam Kadivar, Saadat Molanae. *Tehran University Medical Journal*; Vol. 69, No. 9, December 2011: 529-536 (In Persian)

2009

156. CD44+ cancer cells express higher levels of the anti-apoptotic protein Bcl-2 in breast tumours. Madjd Z, Zare Mehrjerdi A, Sharifi A, Molanaei S, Zohourian S, Asadi Lari M. *Cancer Immunity*. April 2009.vol9.p4.
157. The Concept of Palliative Care Practice among Iranian General Practitioners. Asadi-Lari M, Madjd Z, Afkari ME, Goushegir A, Baradaran HR. . *Iranian Journal of Cancer Prevention*. Vol.2, No 3, summer 2009.
158. OCT4, an embryonic stem cell marker, is expressed in breast, brain and thyroid carcinomas compared to testicular carcinoma. Madjd Z, Hashemi F, Shayanfar N, Farahani E, Zarnani AH, Sharifi AM. *Iranian Journal of Cancer Prevention*. Vol.2, No 4, autum 2009.
- 159. 2008**
160. The need for palliative care services in Iran; an introductory commentary. Asadi-Lari M, Madjd Z, Akbari ME. *Iranian Journal of Cancer Prevention*. Vol.1, No1, 1-5, .2008. Jan
161. Spiritual care at the end of life in the Islamic context, a systematic review, Asadi-Lari M, Madjd Z, Gooshegir. *Iranian Journal of Cancer Prevention*. Vol.1, No 2, July 2008.
162. Gaps in the provision of spiritual care for terminally ill patients in Islamic societies, a systematic review. Mohsen Asadi-Lari, Zahra Madjd, Sayyed Ashrafeddin Goushegir. *Advances in Palliative Medicine* 2008, 73–80.
- 2007**
163. The ubiquitin-binding protein p62 is expressed in breast cancers showing features of aggressive disease. Rolland P, **Madjd Z**, Durrant L, Ellis IO, Layfield R, Spendlove I. *Endocrine Related Cancer* (IF: 5.193). 2007 Mar;14(1):73-80.
164. Up-regulation of MICA on high-grade breast carcinomas. **Madjd Z**, Pinder SE, Spendlove I, Watson NFS, Moss R, Bevan S, Durrant LG. *Cancer immunity*, 2007
- 2006**
165. Expression of the stress related protein MICA is an independent indicator of good prognosis in colorectal cancer patients. Watson NFS, Spendlove I, **Madjd Z**, Moss R, Green A, Ellis IO, Durrant LG, Scholefield JH. *International J Cancer* (IF: 5.007). 2006 Mar 15; 118(6):1445-52.
166. Cytoplasmic expression p27^{KIP-1} is associated with a favourable prognosis in colorectal cancer patients. NFS Watson, LG Durrant, JH Scholefield, **Z Madjd**, D Scrimgeour, I Spendlove, IO Ellis, PM Patel. *World J Gastroenterology* (IF=2.433). 2006 Oct 21,12(39).
167. The p53 Positive Bcl-2 Negative Phenotype is an independent marker of prognosis in breast cancer. Phil Rolland, Ian Spendlove, **Zahra Madjd**, Emad A Rakha, ,Patel Poulam, Ian O. Ellis, Lindy Durrant. *International J Cancer* (IF: 5.007), 22 Dec 2006 .

168. Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC Class I expression correlates with a poor prognosis in early stage patients. Watson NFS, Ramage J, **Madjd Z**, Spendlove I, Ellis IO, Scholefield J, Durrant LG. *Int J Cancer* (IF: 5.007) . 2006 Jan 1; 118(1): 6-10.

2005

169. Evidence that the p53 negative / Bcl-2 positive phenotype is an independent indicator of good prognosis in colorectal cancer: A tissue microarray study of 460 patients. Watson NFS, **Madjd Z**, Ellis IO, Scholefield J, Spendlove I, Durrant LG. *World J Surg Oncology* (IF: 1.20). 2005 Jul 19; 3:47.
170. Expression of the Membrane Complement Regulatory Protein CD59 (Protectin) is Associated with Reduced Survival in Colorectal Cancer patients. Watson NFS, Durrant LG, **Madjd Z**, Ellis IO, Scholefield J, and Spendlove I. *Cancer Immunology Immunotherapy* (2007 IF: 4.8) . 2005 Sep 3;1-8
171. Over-expression of Lewis y/b antigens is associated with decreased survival in lymph node negative breast carcinomas. **Madjd Z**, Parsons T, Watson NFS, Spendlove I, Ellis IO and Durrant LG. *Breast Cancer Research*. (IF: 5.88); 7(5):R780-7. 2005 Jul 28.
172. Do poor prognosis breast tumours express membrane cofactor proteins (CD46)? **Madjd Z**, Durrant LG, Pinder SE, Ellis IO, Ronan J, Rushmere NK and Spendlove. *Cancer Immunology Immunotherapy* (IF: 4.8), 2005;54(2):149-56
173. Total loss of MHC class I molecules is an independent indicator of good prognosis in breast cancers. **Madjd Z**, Pinder SE, Spendlove I, Ellis IO, and Durrant LG. *International J Cancer* (IF: 5.007). 2005 Nov 1; 117(2): 248-55.

2003- 2004

174. Loss of CD55 is associated with aggressive breast tumours. **Madjd Z**, Durrant LG, Bradley R, Spendlove I, Ellis IO, Pinder SE. *Clinical Cancer Research* (IF: 9.625), 2004, 10: 2797-2803
175. Loss of CD59 expression in breast tumours correlates with poor survival. **Madjd Z**, Pinder S E, Paish C, Ellis IO, Carmichael J, Durrant L G. *J Pathology*. (IF: 6.9), 2003, 200: 633-639.

Book:

1. Cancer and Immune system in "**Iran Cancer Report**", in Farsi, 2008, By Cancer Research Centre, Shahid Beheshti University of Medical Sciences
2. **Tissue Microarrays, Evolutionary in Pathology Research**, in Farsi, 2009, By Oncopathology Research Centre, IUMS
3. **What we should know about Breast Cancer**, hundreds questions and answers about Breast cancer , in Farsi, 2010, Oncopathology Research Centre, IUMS
4. **Complement Regulatory Proteins in Breast Cancer**, Madjd Z and Durrant LG In English, 2010, ISBN (978-3-8383-3769-2), published by LAP LAMBERT Academic Publishing AG & Co. KG, Germany, Distribution by Amazon. www.amazon.com

Post-Doctoral Program and projects

1. Dr Leila Eini (2018) Development of therapeutic vaccine based on colorectal cancer stem cell specific Ag in mice model for targeted therapy
2. Dr Mahdyeh Razmi (2020) Production of novel mAb against cancer-stem-cell biomarker, DCLK1-S and its evaluation in gastric cancer
3. Dr Fatemeh Tajik (2022) Clinical significance of novel cancer stem cell marker, DDIT4 in pancreatic cancer
4. Dr Saeed Rahman (2023) Artificial Intelligent (AI) for evaluating immunohistochemical staining of gastric tumour tissues: a novel approach in scoring of pathology slides
5. Dr Amir Hesam Babajani (2023), AI projects, Applying AI in scoring of pancreatic tumours , Artificial intelligence-based clinical histopathological scoring and evaluation for pancreatic cancer: identification of SALL-4A biomarker and analysis of clinical features using tissue microarray samples stained by immunohistochemistry.
6. Mehrab Moradzadeh, Dr Elaheh, Noroozi, Creating Immunohistochemical Images from Hematoxylin-eosin Images in Pathology using Deep Learning

Students and projects

PhD Student supervisor / advisor

1. Mrs Glaviz Adib (Current) . Cold Atmospheric Plasma (CAP) as a novel therapeutic option with current commen medicine for the treatment of colorectal cancer by targeting colorectal cancer stem cells
2. Mrs Fatemeh Alizaman (current). Detection of isoform A of the SALL4 biomarker in the serum of patients with colorectal cancer using a nanobiosensor based on gold nanoparticles.
3. Mr Vahid yavarpour (current). Design and fabrication of immunosensor using platinum nanozyme to detect A-isoform of SALL4 in serum of patients with testicular cancer
4. Miss Sadeghi (current, advisor) *In vitro* RNA therapy of miR-10b in U87MG glioblastoma cell line using umbilical cord stem cell-derived exosomes.
5. Miss Jila Rostami (current, advisor). T Cell engineering with synthetic self-replicating RNA molecule and CRISPR system for ALL CAR T cell therapy.
6. Mr. Mostafa Mostafavi Zadeh (current). Production of Neutralizing monoclonal antibody against spike protein of covid-19.
7. Miss Samaneh Heidari (current). The effect of human acellular amniotic mambrane on reprogramming of breast cancer stem cells
8. Mrs Yasaman Vojgani (current, advisor). Construction of graphene-based gold sensor –MoS₂ gold - to detect CA15.3 protein biomarker
9. Mr Masud Karimi (current, advisor). A cohort study on the expression levels of appoptosis related molecules in the respirtatory cells and the lung cancer biomarkers in the serum of CIVID-19 patients
10. Miss. Farideh Hashemi (current). The effect of cancer stem cell-based therapeutic vaccine on tumorigenesis in colorectal cancer mice model
11. Mrs. Masoumeh Dehghan (current). The effect of Prophylactic and Therapeutic lysate based vaccination of cancer stem cells on tumorigenesis in a mouse model of breast cancer.

12. Mrs. Shima Dorafshan (current). Constructing the metastatic and pre-metastatic microenvironment for Assessment of its impact on decreasing the metastatic burden of circulating tumor cells (CTCs) in murine models
13. Mr. Sadegh Safaei (current). Study of the effect of matrix stiffness in three-dimensional culture conditions on the tumorigenic and metastatic potential in a mouse model of breast cancer
14. Mrs Behjat Kheiri (current, advisor). Evaluation of the synergistic cell growth-inhibition effects of drug and Anti-mir delivery by dendrimer nanoparticles on the breast cancer cells in microfluidic based three-dimensional cell culture systems.
15. Ms Fereshteh Gholizadeh (current, advisor). The Correlation Between EMT-TF Zeb-1 and Snail/Twist in Parenchymal Cells of Metastatic PDAC
16. Mr Edris Choopani (2023, advisor). Evaluation of the role of lnc MALAT1 in the expression of Mir-141 and its target genes in CDK4 / 6 signaling pathway in the inhibition of Breast Cancer Stem Cell
17. Mr. Masoud Hasan Zadeh Makouei (2023, advisor) Production of monoclonal antibodies against tumor markers P53 and Ki67 and estrogen and progesterone receptors and their use for classification of tumor cells in breast cancer patients.
18. Mr. Niknam Lakpour (current). Producing antibody against SALL4 as a novel stem cell marker and detection of this protein in serum and semen for testicular carcinomas (joint project with Avicenna Institute)
19. Mrs. Elham Kalantari (2022) Evaluation of specificity and function of antibody against DCLK1 short isoform (DCLK1-S) in colorectal cancer tissues and cell lines.
20. Mrs. Mina Sharbatoghli (2022). Investigation of genomic variations in circulating tumor DNA of ovarian cancer patients before and after chemotherapy. (joint project with Royan Institute)
21. Ms Azin Aghamajidi (2022, advisor). Evaluation of expression and clinical significance of Genes and proteins of MAGE11 and MAGE6 and miR125b and miR34a in bladder cancer patients.

22. Miss Roya Sajed (2022, advisor), The effect of human term placenta extracellular matrix on breast cancer cell line (MDA-MB-231) phenotype
23. Miss Ayna Yazdanpanah (2022, advisor). E effects of 3 dimensional polycaprolactone scaffold conditioned with ECM of breast cancer metastatic cell line (4T1) for recruitment of circulating tumor cells from blood flow
24. Mr Mohammad Reza Mahmoodi (2021, advisor). Specificity and functional features of anti-RTL1 antibodies in liver and breast cancer cell lines
25. Mr Sina Sarsarshahi (2021). Effect of Bortezomib on radiation-induced urinary bladder dysfunction
26. Miss Faezeh Vakhshiteh (2020, advisor). Investigation of dental pulp mesenchymal stem cell-derived exosomes and exoliposomes loaded with miR-34a to suppress breast cancer cells
27. Miss. Elmira Gheitanchi Mashini (2021). The Effect of exosomes secreted from CSCs of invasive colorectal cancer cell line (HT-29) on drug resistance and invasion of Caco-2 cell line.
28. Mrs Maryam Sahlolbei (2021, advisor). Evidence for the involvement of B Cells and antibody in the pathogenesis of multiple sclerosis in immunized mouse with Recombinant Myelin Basic Protein peptide
29. Mrs. Fahimeh Fattahi (2021). The investigation of systemic effects of regulatory factors (LncRNA, miRNA) on colorectal cancer-related gene and protein expression levels in CRC patients and cancer stem cell.
30. Mrs. Somayeh Vafaei (2021). Investigation and comparison of gene expression profiles of circulating tumor (CTCs) and circulating exosomes in patients with metastatic colorectal cancer (joint project with Royan Institute)
31. Mrs. Marzieh Naseri (2020). Evaluation of the ability of colorectal cancer stem cells (CSCs) lysate-and CSC-derived exosomes (CSC-EXOs)-pulsed dendritic cells (DCs) in induction of CSC-specific CTLs as compared to parental cells lysate-and exosomes-pulsed DCs.

32. Miss. Arezoo Jamali (2021). Evaluation of migration and Anti-tumor Activity of NK CAR-19 cells Overexpressing CXCR4 in B-cell Lymphoma (joint project with Paul-Ehrlich- Institute, Germany)
33. Mrs Zahra Bolandghamat (2020, advisor). Evaluation of miR-154 and miR-381 binding on 3'-UTR of (NAMPT) and the effect of these microRNAs on NAMPT gene expression, protein levels and activity of BC cell lines.
34. Mrs. Maryam Mansouri (2019). The study of circulating cancer stem cells in breast cancer patients, before and after therapy, for monitoring of patients.
35. Miss. Leili Saeednejad Zanjani (2018). Evaluation of biological characteristics and telomerase activity in cancer stem cell (CSCs) compared with low tumorigenic cells in renal cancer (joint project with Oslo University, Norway).
36. Mrs Arezoo Rasti (2018). Evaluation of SMAD4 silencing effect on stemness characteristics of isolated cancer stem cells from renal carcinoma in comparison with low tumorigenic cells in renal cancer.
37. Mr. Alireza Mirzaei (2017). Evaluation of local and circulation colorectal cancer markers DCLK1 and Lgr5, using immune-PCR based assay in order to apply in disease monitoring.
38. Mr Alireza Kororian (2016). In vitro study of the role of microRNA-31 (miR-31) in mediating 5-FU chemo- resistance and metastasis of gastric cancer cell line (AGS)
39. Mr. Mehdi Banitalebi Dehkordi (2015). Differentiation of umbilical cord stem cells in to germ cells.
40. Mr. Abbas Karimi (2015). Analysis of the induction of L1 retrotransposon and toxicity by heavy metals on HepG2 (Hepatocellular carcinoma)
41. Mrs. Tahereh Komeili Movahhed. (2014, advisor) Molecular studies of the siRNA effect on the expression and function and function of BCRP and role of PI3K inhibition in drug resistance to Mitoxantrone in cancer stem cells and MCF7 and HT29 cell lines.

42. Miss. Monireh Mohsenzadegan (2015) Targeting extracellular domain of NGEF using polyclonal antibody in prostate cancer.
43. Miss. Raheleh Roudi (2014). Comparison of gene expression and protein detection of cancer stem cells with non-tumorigenic lung cancer cells. (joint project with Royan Institute)
44. Dr. Mehrdad Nasrollah Zadeh Sabet (2014) Gene expression and protein detection of cancer stem cells of Melanoma, skin squamous cell and basal cell carcinoma compared to non-tumorigenic cells using cDNA microarrays and tissue microarrays (joint project with Royan Institute).
45. Miss. Jaleh Taeb (2014) Preparation and application of polyclonal anti PSCA antibody, its conjugation with magnetic nano- particle and assessment of PSCA expression in prostate tissue.
46. Mrs. Zohreh Saltanatpouri (2016, advisor) Enrichment of cancer stem-like cells (CD133+,CD44+) from HT29 cell line using lentiviral vector expressing E-cadherin sh RNA.
47. Mr Sakhaei (2017, advisor). Coenzyme Q10 Ameliorates Trimethyltin Chloride Neurotoxicity in Experimental Model of Injury in Dentate Gyrus of Hippocampus: A Histopathological and Behavioral Study.
48. Mr. Mohammad Javad Eslami Zadeh (2016, advisor) Investigating the neuroprotective effects of melatonin on beta-amyloid 1-42 induced neurotoxicity and the interaction between melatonin and NF- κ B in rats.
49. Miss. Samira Danyali (2013, advisor) Evaluating the effect of chronic Ritalin intake on adult rat Medical Frontal Cortex.
50. Mr. Mehdi Khaksari (2012, advisor) Evaluation the effects of Apelin-13 on brain injury, brain edema and apoptosis in experimental model of transient focal cerebral ischemia in male rat.

Pathology Residents supervised

1. Dr Samira Ahmadi (2023). Expression of Talin1 in pancreas carcinomas and its association with clinicopathologic and prognosis.

2. Dr Leila Moradi (2022). Expression and clinical significance of CD166 as cancer stem cell marker in gastric carcinomas.
3. Dr Mrzeieh Shahin (2020). Immunohistochemical study of hTERT (human telomerase reverse transcriptase) in different type of testicular carcinomas.
4. Dr Somayeh Shafiee Foroutagheh (2018) Expression of stem cell marker DCLK1 and its relationship with clinicopathological features of bladder cancer patients.
5. Dr. Shirin Sedaghat (2015) Expression of Cancer Stem Cell Markers OCT4 and its relationship with clinicopathological features of bladder cancer patients.
6. Dr. Hossein Kimousi (2013) The Immunohistochemical evaluation of ALDH1 A1 expression and its relation with pathological and clinical characteristics in bladder cancer.
7. Dr. Kambiz Sotoudeh (2012) Expression of C-MET in Gastric Adenoma carcinomas in patients referring to Tehran hospitals.
8. Dr . Adel Karimi (2012). Expression of BRCA1 Protein in Invasive and In Situ Carcinomas and its Relation with Marker of Breast Cancer Stem Cells and Tumor prognostic factors
9. Dr Babak Ramezani (2009) Immunohistochemical investigation of ALDH1 enzyme activity as a functional marker of breast cancer stem cells and progenitor cells and its relationship with tumor pathological characteristics
10. Dr Soheila Nader mohammadi (2017) Associated between P21 and HRAS overexpression and grading, heterogeneity, prognosis, and relapse rate in urothelial cell carcinoma of the bladder.
11. Dr Faezeh Firouzi (2017). The association between overexpression of P53, CK20 and FGFR3 biomarkers and grading ,heterogeneity, and likelihood of prognosis and relapse in urothelial cell carcinoma of the bladder.
12. Dr. Sepideh Razi (2021). Medical students. Exoression of stem cell marker SALL4 and its relationship with clinicopathological features and survival of bladder cancer in patients admitted to Hasheminejad hospital.
13. Dr. Naghmeh Salarieh (2015). Medical student. Investigating the level of cancer stem cell marker (CD44) in prostate tumors and their relationship with tumor pathological characteristics ;Tissue Microarray study

14. Dr. Faezeh Hasani Sadi (2015) Medical student. Immunohistochemical investigation of functional markers of cancer stem cells (ALDH1) in prostate cancer patients and their relationship with tumor pathological features using microarray tissue.
15. Dr Moujan NikPanah (2015). Medical student. Expression level of CD133 marker of stem cells in prostate tumors and their relationship with tumor pathological characteristics; using tissue microarray.